Literature DB >> 24187041

Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy.

Slim Fourati1, Philippe Flandre, Ruxandra Calin, Guislaine Carcelain, Cathia Soulie, Sidonie Lambert-Niclot, Almoustapha Maiga, Zaina Ait-Arkoub, Roland Tubiana, Marc-Antoine Valantin, Brigitte Autran, Christine Katlama, Vincent Calvez, Anne-Genevieve Marcelin.   

Abstract

OBJECTIVES: The relevance of low-level HIV DNA in patients who have undergone prolonged therapy is not well understood. The objective of this study was to determine factors that influence the establishment of low-level HIV DNA in long-term treated patients (excluding treatment since acute infection).
METHODS: This was a cross-sectional study involving 243 patients receiving highly active antiretroviral therapy (HAART) for ≥6 months (median: 9 years of treatment) with plasma HIV RNA <50 copies/mL at the study timepoint, for whom total DNA measurements were performed. Patients treated since early acute infection or receiving cancer chemotherapeutic/immunosuppressive agents were excluded from the study.
RESULTS: Overall, the median HIV DNA was 372 copies/10(6) peripheral blood mononuclear cells (PBMCs). Forty-seven patients had levels of HIV DNA below the limit of detection and 58 patients had low-level HIV DNA (<100 copies/10(6) PBMCs). In multivariate analysis, a low total HIV DNA in HAART-treated patients was clearly associated with a low HIV RNA pre-therapeutic viral load (P < 0.0001), regardless of the cut-off used.
CONCLUSIONS: These results may be helpful to identify candidates for future trials aiming at a functional cure of HIV infection, since low total HIV DNA levels will most likely be a prerequisite of successful immunological control of HIV replication.

Entities:  

Keywords:  ART; HIV immunity; antiretroviral therapy

Mesh:

Substances:

Year:  2013        PMID: 24187041     DOI: 10.1093/jac/dkt428

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  27 in total

1.  Impact of Biological Sex on Immune Activation and Frequency of the Latent HIV Reservoir During Suppressive Antiretroviral Therapy.

Authors:  Shane D Falcinelli; Bonnie E Shook-Sa; Morgan G Dewey; Sumati Sridhar; Jenna Read; Jennifer Kirchherr; Katherine S James; Brigitte Allard; Simon Ghofrani; Erin Stuelke; Caroline Baker; Nadia R Roan; Joseph J Eron; JoAnn D Kuruc; Catalina Ramirez; Cynthia Gay; Katie R Mollan; David M Margolis; Adaora A Adimora; Nancie M Archin
Journal:  J Infect Dis       Date:  2020-11-09       Impact factor: 5.226

Review 2.  Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications.

Authors:  Véronique Avettand-Fènoël; Laurent Hocqueloux; Jade Ghosn; Antoine Cheret; Pierre Frange; Adeline Melard; Jean-Paul Viard; Christine Rouzioux
Journal:  Clin Microbiol Rev       Date:  2016-10       Impact factor: 26.132

Review 3.  Changes in HIV reservoirs during long-term antiretroviral therapy.

Authors:  Feiyu F Hong; John W Mellors
Journal:  Curr Opin HIV AIDS       Date:  2015-01       Impact factor: 4.283

4.  Detectability of HIV Residual Viremia despite Therapy Is Highly Associated with Treatment with a Protease Inhibitor-Based Combination Antiretroviral Therapy.

Authors:  Dolores Vaira; Michel Moutschen; Gilles Darcis; Nathalie Maes; Alexander O Pasternak; Anne-Sophie Sauvage; Frédéric Frippiat; Christelle Meuris; Françoise Uurlings; Marianne Lecomte; Philippe Léonard; Majdouline Elmoussaoui; Karine Fombellida
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

5.  Soluble CD163 and soluble CD14 plasma levels but not cellular HIV-DNA decrease during successful interferon-free anti-HCV therapy in HIV-1-HCV co-infected patients on effective combined anti-HIV treatment.

Authors:  Saverio G Parisi; Samantha Andreis; Carlo Mengoli; Nicola Menegotto; Silvia Cavinato; Renzo Scaggiante; Massimo Andreoni; Giorgio Palù; Monica Basso; Anna Maria Cattelan
Journal:  Med Microbiol Immunol       Date:  2018-03-09       Impact factor: 3.402

6.  Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infection.

Authors:  Joseph J Eron; David A Cooper; Roy T Steigbigel; Bonaventura Clotet; Patrick Yeni; Kim M Strohmaier; Anthony J Rodgers; Richard J Barnard; Bach-Yen T Nguyen; Hedy Teppler
Journal:  Antivir Ther       Date:  2014-10-27

Review 7.  Sexual dimorphism in HIV-1 infection.

Authors:  Anne Rechtien; Marcus Altfeld
Journal:  Semin Immunopathol       Date:  2018-10-01       Impact factor: 9.623

8.  Sex-Based Differences in Human Immunodeficiency Virus Type 1 Reservoir Activity and Residual Immune Activation.

Authors:  Eileen P Scully; Monica Gandhi; Rowena Johnston; Rebecca Hoh; Ainsley Lockhart; Curtis Dobrowolski; Amélie Pagliuzza; Jeffrey M Milush; Christopher A Baker; Valerie Girling; Arlvin Ellefson; Robert Gorelick; Jeffrey Lifson; Marcus Altfeld; Galit Alter; Marcelle Cedars; Ajantha Solomon; Sharon R Lewin; Jonathan Karn; Nicolas Chomont; Peter Bacchetti; Steven G Deeks
Journal:  J Infect Dis       Date:  2019-03-15       Impact factor: 5.226

Review 9.  The Contributions of Clinical Pharmacology to HIV Cure Research.

Authors:  Courtney V Fletcher; Shetty Ravi Dyavar; Arpan Acharya; Siddappa N Byrareddy
Journal:  Clin Pharmacol Ther       Date:  2021-04-18       Impact factor: 6.903

Review 10.  Addressing an HIV cure in LMIC.

Authors:  Sherazaan D Ismail; Joshua Pankrac; Emmanuel Ndashimye; Jessica L Prodger; Melissa-Rose Abrahams; Jamie F S Mann; Andrew D Redd; Eric J Arts
Journal:  Retrovirology       Date:  2021-08-03       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.